State Street Corp raised its stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 0.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,438,814 shares of the medical equipment provider's stock after acquiring an additional 10,179 shares during the quarter. State Street Corp owned approximately 2.69% of Masimo worth $191,837,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in MASI. Assenagon Asset Management S.A. boosted its position in Masimo by 643.8% in the second quarter. Assenagon Asset Management S.A. now owns 50,740 shares of the medical equipment provider's stock valued at $6,390,000 after buying an additional 43,918 shares in the last quarter. Fifth Third Bancorp boosted its holdings in shares of Masimo by 16.4% in the 2nd quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider's stock worth $88,000 after acquiring an additional 98 shares in the last quarter. Raymond James Trust N.A. boosted its holdings in shares of Masimo by 14.3% in the 2nd quarter. Raymond James Trust N.A. now owns 6,414 shares of the medical equipment provider's stock worth $808,000 after acquiring an additional 800 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Masimo by 8.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,877 shares of the medical equipment provider's stock worth $992,000 after acquiring an additional 610 shares during the last quarter. Finally, Versor Investments LP acquired a new stake in Masimo during the 2nd quarter valued at $665,000. Institutional investors and hedge funds own 85.96% of the company's stock.

MASI has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their price objective on Masimo from $171.00 to $193.00 and gave the stock an "overweight" rating in a research note on Wednesday. BTIG Research upped their price target on shares of Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Raymond James upgraded shares of Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price objective for the company in a research report on Wednesday, November 6th. Stifel Nicolaus reiterated a "buy" rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Masimo presently has a consensus rating of "Moderate Buy" and an average target price of $170.67.

View Our Latest Stock Report on MASI

Shares of NASDAQ:MASI opened at $175.08 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The stock has a market cap of $9.37 billion, a price-to-earnings ratio of 120.74 and a beta of 1.01. The company has a 50 day moving average of $156.51 and a 200-day moving average of $132.80. Masimo Co. has a one year low of $101.61 and a one year high of $178.87.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business's quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 EPS. On average, sell-side analysts forecast that Masimo Co. will post 4.03 earnings per share for the current year.

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Masimo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.

While Masimo currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.